Clicky

Galectin Therapeutics Inc.(GALT)

Description: Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.


Keywords: Cancer Tumor Alcohol Hepatitis Melanoma Liver Disease Europe Steatohepatitis Non Alcoholic Fatty Liver Disease Therapies For Cancer Liver Fibrosis Fibrotic Disease Lectins Combination Therapy Galectin Fatty Liver Disease Galectin 3 Galecto Biotech Lactose Fatty Liver

Home Page: galectintherapeutics.com

GALT Technical Analysis

4960 Peachtree Industrial Boulevard
Norcross, GA 30071
United States
Phone: 678 620 3186


Officers

Name Title
Mr. Joel Lewis Pres, CEO & Director
Mr. Jack W. Callicutt CPA, CPA CFO, Treasurer & Corp. Sec.
Dr. Pol F. Boudes M.D., Ph.D. Chief Medical Officer
Robert Tritt Gen. Counsel
Ms. Beth Knowles Exec. Assistant & Officer Mang.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 207.6975
Price-to-Sales TTM: 0
IPO Date: 2002-09-09
Fiscal Year End: December
Full Time Employees: 9
Back to stocks